Monsanto Co. (NYSE:MON) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided EPS guidance of $4.50-4.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.72.

Monsanto Co. (NYSE:MON) opened at 102.71 on Thursday. The company has a market cap of $44.99 billion, a PE ratio of 34.37 and a beta of 1.01. Monsanto Co. has a 52 week low of $83.73 and a 52 week high of $114.26. The stock has a 50 day moving average of $100.96 and a 200 day moving average of $104.20.

Monsanto (NYSE:MON) last announced its earnings results on Wednesday, October 5th. The company reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.09. The business earned $2.56 billion during the quarter, compared to the consensus estimate of $2.38 billion. Monsanto had a net margin of 9.89% and a return on equity of 46.07%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.19) earnings per share. Equities research analysts predict that Monsanto Co. will post $4.73 EPS for the current fiscal year.

Earnings History and Estimates for Monsanto (NYSE:MON)

A number of brokerages have commented on MON. S&P Equity Research reiterated a positive rating on shares of Monsanto in a report on Thursday, September 15th. Monness Crespi & Hardt reduced their target price on shares of Monsanto from $130.00 to $128.00 and set a buy rating for the company in a report on Monday, October 3rd. Vetr upgraded shares of Monsanto from a buy rating to a strong-buy rating and set a $117.09 target price for the company in a report on Wednesday, August 3rd. TheStreet downgraded shares of Monsanto from a buy rating to a hold rating in a report on Monday, September 12th. Finally, Deutsche Bank AG upped their price objective on shares of Monsanto from $118.00 to $128.00 and gave the company a buy rating in a report on Thursday, September 15th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $114.06.

In other Monsanto news, EVP Steven Mizell sold 310 shares of the firm’s stock in a transaction on Monday, October 10th. The stock was sold at an average price of $103.09, for a total value of $31,957.90. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kerry J. Preete sold 2,745 shares of the firm’s stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $100.96, for a total value of $277,135.20. Following the completion of the transaction, the executive vice president now owns 50,056 shares in the company, valued at approximately $5,053,653.76. The disclosure for this sale can be found here. 0.88% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/12/01/monsanto-co-mon-issues-fy17-earnings-guidance.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC raised its position in shares of Monsanto by 41.3% in the second quarter. FMR LLC now owns 16,593,757 shares of the company’s stock worth $1,715,960,000 after buying an additional 4,851,499 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Monsanto by 0.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 14,893,956 shares of the company’s stock worth $1,540,185,000 after buying an additional 38,316 shares during the last quarter. Capital International Investors raised its position in shares of Monsanto by 6.2% in the second quarter. Capital International Investors now owns 8,187,701 shares of the company’s stock worth $846,690,000 after buying an additional 476,848 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Monsanto by 50.4% in the second quarter. TIAA CREF Investment Management LLC now owns 4,658,464 shares of the company’s stock worth $481,732,000 after buying an additional 1,560,646 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Monsanto by 5.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,023,050 shares of the company’s stock worth $206,756,000 after buying an additional 106,085 shares during the last quarter. Institutional investors own 73.94% of the company’s stock.

About Monsanto

Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and precision agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.

5 Day Chart for NYSE:MON

Receive News & Stock Ratings for Monsanto Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monsanto Co. and related stocks with our FREE daily email newsletter.